89bio, Inc.
ETNB
$0.03
Change (1 day)
$16.63
Year High
$6.58
Year Low
Categories
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Earnings for 89bio, Inc. (ETNB)
Earnings in 2023 (TTM): $-138,322,000
According to 89bio, Inc.'s latest financial reports the company's current earnings (TTM) are $-138,322,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of 89bio, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-138,322,000 | $-142,189,000 |
| 2022 | $-102,007,000 | $-102,026,000 |
| 2021 | $-90,269,000 | $-90,122,000 |
| 2020 | $-49,558,000 | $-49,499,000 |
| 2019 | $-57,202,000 | $-57,420,000 |
| 2018 | $-16,148,000 | $-16,176,000 |